Byetta Injection
NDC Package 0310-6512-01
Package Information
Byetta (exenatide) injection is bYETTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Limitations of Use•BYETTA contains exenatide. This formulation utilizes a injection delivery system. Marketed by Astrazeneca Pharmaceuticals Lp, this product is identified by NDC 0310-6512 and is authorized under FDA application NDA021773.
Identification & Billing
- RxCUI: 847910 - exenatide 10 MCG, 250 MCG/ML in 2.4 mL Pen Injector
- RxCUI: 847910 - 60 ACTUAT exenatide 0.01 MG/ACTUAT Pen Injector
- RxCUI: 847910 - exenatide 10 MCG/ACTUAT Pen Injector, 60 ACTUAT
- RxCUI: 847910 - exenatide 250 MCG/ML Pen Injector, 2.4 ML
- RxCUI: 847913 - Byetta 10 MCG, 250 MCG/ML in 2.4 mL Pen Injector
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0310 - Astrazeneca Pharmaceuticals Lp
- 0310-6512 - Byetta
- 0310-6512-01 - 1 CARTRIDGE in 1 CARTON / 1.2 mL in 1 CARTRIDGE
- 0310-6512 - Byetta
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0310-6512). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0310-6512-01 identifies a specific commercial package of 1 cartridge in 1 carton / 1.2 ml in 1 cartridge of Byetta, a human prescription drug labeled by Astrazeneca Pharmaceuticals Lp. This injection is formulated for subcutaneous use and contains exenatide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Astrazeneca Pharmaceuticals Lp on December 10, 2014.
How is this Astrazeneca Pharmaceuticals Lp product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00310651201. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 1.2 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.